KDT’s $100m investment in Israel-based ultrasound surgery technology developer InSightec as part of the portfolio company’s series F round of up to $150m gives it a post-money valuation of $1.3bn.
It is KDT’s second direct investment in InSightec after leading the $150m series E round at the end of 2017. InSightec’s Exablate Neuro incisionless neurosurgery platform is now approved by the US regulator to treat certain movement disorders in patients suffering from essential tremor and tremor-dominant Parkinson’s disease who have not responded to medications.
Chase Koch, president of KDT, said: ” InSightec’s focused ultrasound technology is disrupting the way surgery has been performed for generations. “KDT is focused on empowering innovative companies and helping them realize their potential to improve the lives of millions of people. “
The financing will support continued research to evaluate focused ultrasound to treat these and other disorders.
Separate to InSightec, ultrasound has increasingly been used in other ways, with the US and Chinese governments investing in low- and high-pitch sound devices for riot control situations or potential military applications.
But InSightec is concentrating on the medical aspects. Maurice Ferré, CEO and chairman of InSightec, said: “Our partnership with KDT and other investors is helping to fuel our momentum as a rapidly growing number of medical institutions adopt our focused ultrasound technology.”
